Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Health Technology Assessment Real-World Evidence FDA

In Case You Missed It: RWE, US FDA Commissioner Hearings, 2021 Approval Trends, And More

  • News

Executive Summary

Start the new year by catching up with these key stories posted by the Pink Sheet in late December.

You may also be interested in...



Pink Sheet Podcast: Makena Withdrawal Hearing, Califf And Trust In FDA, COVID-19 Pill Dispensing

Pink Sheet reporters and editors discuss how the hearings for the withdrawal of Avastin’s accelerated approval in breast cancer could inform the same process for Makena, Robert Califf’s view that public trust in the agency will be rebuilt, and a request to increase the dispensing fees associated with COVID-19 treatments Paxlovid and molnupiravir.

In Case You Missed It … News On Cheaper CAR-Ts, EU Approval Records, And More

We clean out your Martin Luther King Day inbox so you don't have to.

Pink Sheet Podcast: Califf Confirmation Hearing, COVID-19 Vaccine Changes, Cancer Drugs From China

Pink Sheet reporters and editors discuss US FDA commissioner nominee Robert Califf’s Senate confirmation hearing, new COVID-19 vaccine recommendations from the US CDC, and issues related to US approval of China-developed cancer drugs.

Table

View full table

Topics

Tags:
Health Technology Assessment Real-World Evidence FDA
UsernamePublicRestriction

Register

PS145454

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By